tradingkey.logo
tradingkey.logo
Search

SpaceX Valuation Hits $400 Billion in New Buyback — Up 5x Since 2021

TradingKeyJul 16, 2025 11:57 AM
facebooktwitterlinkedin
View all comments0

TradingKey - Compared to Tesla, the financial markets appear to be placing even greater value on Elon Musk’s flagship company, SpaceX, which has just announced a new $1.25 billion share buyback program — pushing its valuation to an estimated $400 billion, over five times higher than in 2021.

According to sources cited by Bloomberg, SpaceX is offering to buy back shares from early employees and investors at $212 per share, significantly above its previous valuation of $350 billion as of December 2024 (at $185 per share ).

This marks the latest in a series of buybacks that have allowed early stakeholders to cash out while reinforcing internal incentives and confidence in future growth.

SpaceX vs. Tesla: A Tale of Two Valuations

Back in early 2021, Sequoia Capital invested in SpaceX at a valuation of $74 billion — meaning the company has grown over 5.4x since then.

In contrast, Tesla’s valuation has risen more modestly — from $760 billion to $1 trillion — an increase of just 32% over the same period.

Analysts note that SpaceX’s rising buyback price and continued share repurchase activity signal strong forward-looking confidence in the company’s long-term value growth.

Market Leader in Commercial Space

SpaceX remains the dominant player in the commercial launch market, and its Starlink division operates the world’s largest low-orbit satellite constellation, with over 7,000 active satellites — more than 60% of all operational satellites globally.

Starlink is estimated to have generated $8.2 billion in revenue in 2024, with over 5 million users — further strengthening SpaceX’s commercial foundation.

Earlier in June, during a public feud between Musk and President Trump, Musk threatened to cancel federal contracts — a move that analysts said could challenge U.S. space security, highlighting SpaceX’s strategic importance.

This week, reports emerged that SpaceX is planning to conduct pharmaceutical research in orbit using its Starship rocket, opening a new potential revenue stream for the world’s most valuable private company.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

tradingkey.logo
* References, analysis, and trading strategies are provided by the third-party provider, Trading Central, and the point of view is based on the independent assessment and judgement of the analyst, without considering the investment objectives and financial situation of the investors.
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.